Diana Ernst, RPh, Author at Cancer Therapy Advisor
Diana Ernst, RPh

Diana Ernst, RPh

Editorial Director https://www.cancertherapyadvisor.com
Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

First-in-Class Treatment Approved for Advanced Breast Cancer

The FDA has approved Piqray (alpelisib; Novartis) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Next post in Chronic Lymphocytic Leukemia